- AU$14.01m
- AU$11.04m
- AU$0.36m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.06 | ||
| Price to Tang. Book | 6.87 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 38.45 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -158.93% | ||
| Return on Equity | -317.64% | ||
| Operating Margin | -1496.28% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.06 | 0.12 | 0.32 | 0.61 | 0.36 | n/a | n/a | 11.74% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HeraMED Limited is an Australia-based medical data and technology company. The Company is engaged in the digital transformation of maternity care by transforming the prenatal and postpartum experience with its hybrid maternity care platform. The Company offers a proprietary platform that utilizes hardware and software to reshape the doctor/patient relationship using its clinically validated in-home fetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data. The HeraBEAT medical device is used by pregnant women in Europe, the United States, Israel and Australia. The Company’s proprietary offering, HeraCARE, is engineered to offer a fully integrated maternal health ecosystem designed to deliver care to ensure expectant mothers are engaged, informed and well-supported, allowing healthcare professionals to provide quality care and enable early detection and prevention of potential risks.
Directors
- Ronald Weinberger NEC
- David Groberman CEO
- Sivan Sadan CFO (48)
- Tal Slonim COO
- Jonathan Hart SEC
- Doron Birger NED (70)
- David Hinton NED
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 21st, 2018
- Public Since
- January 1st, 1970
- No. of Shareholders
- 1,245
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 875,602,742
- Address
- Level 2, PERTH, 6005
- Web
- https://www.hera-med.com/
- Phone
- Auditors
- BDO Audit (WA) PTY LTD
Upcoming Events for HMD
Hera Med Ltd Annual Shareholders Meeting
Similar to HMD
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
Aroa Biosurgery
Australian Stock Exchange - SEATS
FAQ
What is the Heramed share price?
As of Today at 21:05 UTC, shares in Heramed are trading at AU$0.02. This share price information is delayed by 15 minutes.
How has the Heramed share price performed this year?
Shares in Heramed last closed at AU$0.02 and the price had moved by -8.57% over the past 365 days. In terms of relative price strength the Heramed share price has underperformed the ASX All Ordinaries Index by -13.18% over the past year.
What are the analyst and broker recommendations for Heramed?
There is no consensus recommendation for this security.
Find out moreWhat is the Heramed dividend yield?
Heramed does not currently pay a dividend.
Does Heramed pay a dividend?
Heramed does not currently pay a dividend.
When does Heramed next pay dividends?
Heramed does not currently pay a dividend.
How do I buy Heramed shares?
To buy shares in Heramed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Heramed?
As of the previous close price of AU$0.02, shares in Heramed had a market capitalisation of AU$14.01m.
Where are Heramed shares listed?
Here are the trading details for Heramed:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: HMD
What kind of share is Heramed?
Based on an overall assessment of its quality, value and momentum Heramed is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Heramed share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Heramed share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Heramed. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -26.56%.
As of the last closing price of AU$0.02, shares in Heramed were trading -19.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Heramed PE Ratio?
The Heramed PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Heramed?
Heramed's management team is headed by:
- Ronald Weinberger - NEC
- David Groberman - CEO
- Sivan Sadan - CFO
- Tal Slonim - COO
- Jonathan Hart - SEC
- Doron Birger - NED
- David Hinton - NED